A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma
Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4401-4404
10.1182/blood-2022-167008